Compass Therapeutics (NASDAQ:CMPX) Hits New 1-Year High on Analyst Upgrade

Compass Therapeutics, Inc. (NASDAQ:CMPX) shares hit a new 52-week high during trading on Monday after Jefferies Financial Group raised their price target on the stock from $7.00 to $8.00. Jefferies Financial Group currently has a buy rating on the stock. Compass Therapeutics traded as high as $3.95 and last traded at $3.94, with a volume of 359782 shares. The stock had previously closed at $3.50.

Other analysts have also issued reports about the company. D. Boral Capital reiterated a “buy” rating and set a $32.00 price target on shares of Compass Therapeutics in a report on Wednesday, January 8th. HC Wainwright reaffirmed a “buy” rating and set a $10.00 target price on shares of Compass Therapeutics in a research report on Wednesday, January 8th. Leerink Partnrs downgraded shares of Compass Therapeutics from a “strong-buy” rating to a “hold” rating in a report on Friday, November 15th. Finally, Leerink Partners downgraded shares of Compass Therapeutics from an “outperform” rating to a “market perform” rating and decreased their price objective for the stock from $5.00 to $4.00 in a report on Friday, November 15th. Two research analysts have rated the stock with a hold rating and five have assigned a buy rating to the stock. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average price target of $11.17.

Institutional Investors Weigh In On Compass Therapeutics

A number of institutional investors and hedge funds have recently bought and sold shares of CMPX. Barclays PLC increased its position in shares of Compass Therapeutics by 195.4% during the 3rd quarter. Barclays PLC now owns 170,245 shares of the company’s stock valued at $314,000 after purchasing an additional 112,614 shares during the last quarter. SG Americas Securities LLC raised its stake in shares of Compass Therapeutics by 921.6% during the fourth quarter. SG Americas Securities LLC now owns 395,017 shares of the company’s stock worth $573,000 after acquiring an additional 356,352 shares in the last quarter. Geode Capital Management LLC raised its stake in shares of Compass Therapeutics by 0.8% during the third quarter. Geode Capital Management LLC now owns 2,309,778 shares of the company’s stock worth $4,251,000 after acquiring an additional 19,095 shares in the last quarter. The Manufacturers Life Insurance Company bought a new stake in shares of Compass Therapeutics in the 3rd quarter worth approximately $79,000. Finally, Cubist Systematic Strategies LLC purchased a new stake in shares of Compass Therapeutics in the 2nd quarter valued at $41,000. 68.43% of the stock is owned by hedge funds and other institutional investors.

Compass Therapeutics Trading Down 6.4 %

The company has a market cap of $502.20 million, a P/E ratio of -9.86 and a beta of 1.17. The company’s fifty day moving average is $2.16 and its 200 day moving average is $1.76.

Compass Therapeutics (NASDAQ:CMPX) last posted its quarterly earnings results on Tuesday, November 12th. The company reported ($0.08) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.11) by $0.03. Analysts anticipate that Compass Therapeutics, Inc. will post -0.35 EPS for the current year.

Compass Therapeutics Company Profile

Compass Therapeutics, Inc, a clinical-stage oncology-focused biopharmaceutical company, engages in developing antibody-based therapeutics to treat various human diseases in the United States. The company's lead product candidates include CTX-009, a bispecific antibody that blocks Delta-like ligand 4 a ligand of Notch-1, and vascular endothelial growth factor A signaling pathways, which are critical to angiogenesis and tumor vascularization; and CTX-471, an IgG4 monoclonal antibody that is an agonist of CD137, a key co-stimulatory receptor on immune cells.